Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1

Affiliations

• ¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
• ² Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
• ³ Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
• ⁴ Ludwig Center at Harvard, Boston, Massachusetts, USA.
• ⁵ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
• ⁶ Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, and Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
• ⁷ Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA.
• ⁸ Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
• ⁹ Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.